Advertisement

Neurological Sciences

, Volume 40, Issue 1, pp 167–173 | Cite as

High-sensitivity C-reactive protein and high mobility group box-1 levels in Parkinson’s disease

  • Aslıhan Baran
  • Mahmut Bulut
  • Mehmet Cemal Kaya
  • Özlem Demirpençe
  • Bünyamin Sevim
  • Eşref Akıl
  • Sefer Varol
Original Article

Abstract

Various immunologic and inflammatory factors are contributed to pathogenesis of Parkinson’s disease (PD). High mobility group box-1 (HMGB1) is a protein that plays certain roles in inflammation, DNA repair, transcription, somatic recombination, cell differentiation, cell migration, neuronal development, and neurodegeneration. The aim of the present study was to evaluate the serum levels of HMGB1 and high-sensitivity C-reactive protein (hs-CRP) among patients with Parkinson’s disease and healthy controls. This study includes 30 patients with PD and 30 healthy controls, matched sex, age, body mass index, and smoking status. HMGB1 and hs-CRP serum levels were compared between the groups. The diagnostic performance of HMGB1 and hs-CRP was evaluated with receiver operating characteristic (ROC) curve analysis. HMGB1 levels were significantly higher in PD patients than in controls. Hs-CRP levels were significantly higher in PD patients than in controls There was a moderate correlation between hs-CRP and HMGB1 levels in the patient group. The cut-off value of HMGB1 level for the prediction of PD was determined as 32.8 ng/mL with 80% sensitivity and 60% specificity (p = 0.006). The cut-off value of hs-CRP level for the prediction of PD was determined as 0.63 mg/L with 66.7% sensitivity and 77.7% specificity (p = 0.007). This study demonstrates for the first time the association between HMGB1, hs-CRP, and PD. We found that HMGB1 and hs-CRP levels to be significantly higher in the PD patients than in the normal controls. As a result of the ROC curve analysis, HMGB1 and hs-CRP levels may be fair markers in the diagnosis of PD.

Keywords

Parkinson’s disease High mobility group box-1 High-sensitivity C-reactive protein Inflammation 

Notes

Compliance with ethical standards

All investigators who took part in this study signed the Declaration of Helsinki, and this study was conducted after the necessary administrative permits and approval of local ethics committee was in place (Ethics committe approval number:720/20).

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Pringsheim T, Jette N, Frolkis A, Steeves TD (2014) The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 29(13):1583–1590.  https://doi.org/10.1002/mds.25945 CrossRefGoogle Scholar
  2. 2.
    Hornykiewicz O (2006) The discovery of dopamine deficiency in the parkinsonian brain. J Neural Transm Suppl 70:9–15CrossRefGoogle Scholar
  3. 3.
    Yang Y, Han CY, Guo L, Guan QB (2018) High expression of the HMGB1-TLR4 axis and its downstream signaling factors in patients with Parkinson’s disease and the relationship of pathological staging. Brain Behav 8(4):e00948.  https://doi.org/10.1002/brb3.948 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Vivekanantham S, Shah S, Dewji R, Dewji A, Khatri C, Ologunde R (2015) Neuroinflammation in Parkinson’s disease: role in neurodegeneration and tissue repair. Int J Neurosci 125(10):717–725.  https://doi.org/10.3109/00207454.2014.982795 CrossRefPubMedGoogle Scholar
  5. 5.
    Chao Y, Wong SC, Tan EK (2014) Evidence of inflammatory system involvement in Parkinson’s disease. Biomed Res Int 2014:308654.  https://doi.org/10.1155/2014/308654 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Zhang J, McCauley MJ, Maher LJ 3rd, Williams MC, Israeloff NE (2009) Mechanism of DNA flexibility enhancement by HMGB proteins. Nucleic Acids Res 37(4):1107–1114.  https://doi.org/10.1093/nar/gkn1011 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kang HJ, Lee H, Choi HJ, Youn JH, Shin JS, Ahn YH, Yoo JS, Paik YK, Kim H (2009) Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers. Lab Investig 89(8):948–959.  https://doi.org/10.1038/labinvest.2009.47 CrossRefPubMedGoogle Scholar
  8. 8.
    Thomas JO, Travers AA (2001) HMG1 and 2, and related ‘architectural’ DNA-binding proteins. Trends Biochem Sci 26(3):167–174CrossRefGoogle Scholar
  9. 9.
    Muller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, Agresti A, Beltrame M, Bianchi ME (2001) New EMBO members’ review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J 20(16):4337–4340.  https://doi.org/10.1093/emboj/20.16.4337 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Todorova J, Pasheva E (2012) High mobility group B1 protein interacts with its receptor RAGE in tumor cells but not in normal tissues. Oncol Lett 3(1):214–218.  https://doi.org/10.3892/ol.2011.459 CrossRefPubMedGoogle Scholar
  11. 11.
    Park JS, Arcaroli J, Yum HK, Yang H, Wang H, Yang KY, Choe KH, Strassheim D, Pitts TM, Tracey KJ, Abraham E (2003) Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Phys Cell Physiol 284(4):C870–C879.  https://doi.org/10.1152/ajpcell.00322.2002 CrossRefGoogle Scholar
  12. 12.
    Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Naworth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, Coyle AJ (2007) Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 8(5):487–496.  https://doi.org/10.1038/ni1457 CrossRefPubMedGoogle Scholar
  13. 13.
    Fang P, Schachner M, Shen YQ (2012) HMGB1 in development and diseases of the central nervous system. Mol Neurobiol 45(3):499–506.  https://doi.org/10.1007/s12035-012-8264-y CrossRefPubMedGoogle Scholar
  14. 14.
    Lindersson EK, Hojrup P, Gai WP, Locker D, Martin D, Jensen PH (2004) alpha-Synuclein filaments bind the transcriptional regulator HMGB-1. Neuroreport 15(18):2735–2739PubMedGoogle Scholar
  15. 15.
    Gao HM, Zhou H, Zhang F, Wilson BC, Kam W, Hong JS (2011) HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci 31(3):1081–1092.  https://doi.org/10.1523/JNEUROSCI.3732-10.2011 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Rizzi L, Marques FC, Rosset I, Moriguchi EH, Picon PD, Chaves ML, Roriz-Cruz M (2014) C-reactive protein and cognition are unrelated to leukoaraiosis. ScientificWorldJournal 2014:121679–121678.  https://doi.org/10.1155/2014/121679 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Song IU, Kim YD, Cho HJ, Chung SW (2013) Is neuroinflammation involved in the development of dementia in patients with Parkinson’s disease? Intern Med 52(16):1787–1792CrossRefGoogle Scholar
  18. 18.
    Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F (2005) Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol 4(6):371–380.  https://doi.org/10.1016/S1474-4422(05)70099-5 CrossRefPubMedGoogle Scholar
  19. 19.
    Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184CrossRefGoogle Scholar
  20. 20.
    Song IU, Chung SW, Kim JS, Lee KS (2011) Association between high-sensitivity C-reactive protein and risk of early idiopathic Parkinson’s disease. Neurol Sci 32(1):31–34.  https://doi.org/10.1007/s10072-010-0335-0 CrossRefPubMedGoogle Scholar
  21. 21.
    Santoro M, Maetzler W, Stathakos P, Martin HL, Hobert MA, Rattay TW, Gasser T, Forrester JV, Berg D, Tracey KJ, Riedel G, Teismann P (2016) In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson’s disease which can be attenuated by glycyrrhizin. Neurobiol Dis 91:59–68.  https://doi.org/10.1016/j.nbd.2016.02.018 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427–442CrossRefGoogle Scholar
  23. 23.
    Lee J, Taneja V, Vassallo R (2012) Cigarette smoking and inflammation: cellular and molecular mechanisms. J Dent Res 91(2):142–149.  https://doi.org/10.1177/0022034511421200 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Sasaki T, Liu K, Agari T, Yasuhara T, Morimoto J, Okazaki M, Takeuchi H, Toyoshima A, Sasada S, Shinko A, Kondo A, Kameda M, Miyazaki I, Asanuma M, Borlongan CV, Nishibori M, Date I (2016) Anti-high mobility group box 1 antibody exerts neuroprotection in a rat model of Parkinson’s disease. Exp Neurol 275(Pt 1):220–231.  https://doi.org/10.1016/j.expneurol.2015.11.003 CrossRefPubMedGoogle Scholar
  25. 25.
    Kawahara K, Biswas KK, Unoshima M, Ito T, Kikuchi K, Morimoto Y, Iwata M, Tancharoen S, Oyama Y, Takenouchi K, Nawa Y, Arimura N, Jie MX, Shrestha B, Miura N, Shimizu T, Mera K, Arimura S, Taniguchi N, Iwasaka H, Takao S, Hashiguchi T, Maruyama I (2008) C-reactive protein induces high-mobility group box-1 protein release through activation of p38MAPK in macrophage RAW264.7 cells. Cardiovasc Pathol 17(3):129–138.  https://doi.org/10.1016/j.carpath.2007.08.006 CrossRefPubMedGoogle Scholar
  26. 26.
    Nawaz MI, Mohammad G (2015) Role of high-mobility group box-1 protein in disruption of vascular barriers and regulation of leukocyte-endothelial interactions. J Recept Signal Transduct Res 35(4):340–345.  https://doi.org/10.3109/10799893.2014.984309 CrossRefPubMedGoogle Scholar
  27. 27.
    Akil E, Bulut A, Kaplan I, Ozdemir HH, Arslan D, Aluclu MU (2015) The increase of carcinoembryonic antigen (CEA), high-sensitivity C-reactive protein, and neutrophil/lymphocyte ratio in Parkinson’s disease. Neurol Sci 36(3):423–428.  https://doi.org/10.1007/s10072-014-1976-1 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of NeurologyPark HospitalMalatyaTurkey
  2. 2.Department of Biochemistry, Faculty of MedicineDicle UniversityDiyarbakırTurkey
  3. 3.Department of Psychiatry, Faculty of MedicineDicle UniversityDiyarbakırTurkey
  4. 4.Department of Biochemistry, Faculty of MedicineCumhuriyet UniversitySivasTurkey
  5. 5.Department of Neurology, Faculty of MedicineDicle UniversityDiyarbakırTurkey

Personalised recommendations